Shares of Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) fell 2% on Wednesday . The stock traded as low as $0.65 and last traded at $0.69. 774,335 shares traded hands during trading, an increase of 39% from the average session volume of 556,340 shares. The stock had previously closed at $0.68.

The company has a market cap of $16.33, a P/E ratio of 4.38 and a beta of 3.29.

Eleven Biotherapeutics (NASDAQ:EBIO) last announced its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter. Eleven Biotherapeutics had a net margin of 11.28% and a return on equity of 4.26%. equities research analysts forecast that Eleven Biotherapeutics, Inc. will post -1.85 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in EBIO. Vanguard Group Inc. raised its stake in shares of Eleven Biotherapeutics by 17.4% in the 2nd quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 30,600 shares in the last quarter. Spark Investment Management LLC bought a new stake in shares of Eleven Biotherapeutics in the 2nd quarter worth $148,000. Virtu KCG Holdings LLC bought a new stake in shares of Eleven Biotherapeutics in the 2nd quarter worth $175,000. Finally, Municipal Employees Retirement System of Michigan bought a new stake in shares of Eleven Biotherapeutics in the 3rd quarter worth $382,000. 5.00% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Eleven Biotherapeutics, Inc. (EBIO) Stock Price Down 2%” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Receive News & Stock Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.